Document is current

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
https://doi.org/10.1136/jitc-2021-002742

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Dysregulation of CD4⁺and CD8⁺resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
https://doi.org/10.1136/jitc-2023-008628

Managing IBD in patients with previous cancers
https://doi.org/10.1136/flgastro-2022-102187

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
https://doi.org/10.1136/jitc-2021-002850

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
https://doi.org/10.1136/jitc-2021-003277

Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
https://doi.org/10.1200/jco.2024.42.16_suppl.2661

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111

Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.9553

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
https://doi.org/10.1136/jitc-2021-003551

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814

816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps2680

696 Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial
https://doi.org/10.1136/jitc-2022-sitc2022.0696

Cardiovascular toxicity of immune therapies for cancer
https://doi.org/10.1136/bmj-2023-075859

Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540

Clinical Characteristics and Mechanisms of Acute Myocarditis
https://doi.org/10.1161/circresaha.124.324674

Evaluation and management of chest pain from cardiovascular causes in female patients
https://doi.org/10.1136/bmj-2025-086177

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis.
https://doi.org/10.1200/jco.2024.42.16_suppl.2517

Effect of fecal transplantation on patients’ reported outcome after immune checkpoint inhibitor colitis.
https://doi.org/10.1200/jco.2023.41.16_suppl.2645

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776